Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Fake Wegovy: Pharma Giant Novo Nordisk Reportedly Steps Up Efforts Tackling Illegal Weight Loss Drugs Sold Online
08:02am, Monday, 18'th Dec 2023
One of India's leading online marketplaces is working with pharma giant Novo Nordisk to tackle illegal sales of popular weight loss drug Wegovy, Reuters reported Monday, as its soaring popularity and
Exclusive: IndiaMART is working with Novo Nordisk to halt illegal Wegovy sales -source
08:39pm, Sunday, 17'th Dec 2023
Indian online marketplace IndiaMART has been removing unauthorized listings of Novo Nordisk's blockbuster weight-loss drug Wegovy after holding talks with the Danish drugmaker in early October, a sour
Ozempic and Wegovy lead Novo Nordisk to Yahoo Finance's Company of the Year
10:00am, Sunday, 17'th Dec 2023
Novo Nordisk (NVO) and more specifically its weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street. The company's financial performance, impact and buzz has
The New Magnificent 7: 7 Stocks Rising to Prominence
08:55am, Friday, 15'th Dec 2023
The magnificent seven stocks have had a fantastic 2023. Those firms dominate Silicon Valley and are amongst seven of the largest eight firms globally, as measured by market capitalization.
Arecor's novel drug formulations could help cut burden on hospitals
07:15am, Friday, 15'th Dec 2023
Arecor Therapeutics PLC (AIM:AREC)'s chief executive Sarah Howell said the company is at an advanced stage of recruiting patients for phase one trials of rapid ultra-concentrated insulin and should be
Ozempic Isn't the Best Weight-Loss Treatment Anymore. Here's Why That Shouldn't Matter to Novo Nordisk Investors.
09:10am, Thursday, 14'th Dec 2023
In studies, Eli Lilly's Mounjaro has demonstrated that it is more effective in helping people lose weight than Ozempic. Street analysts project the weight-loss market to be massive.
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
10:39pm, Wednesday, 13'th Dec 2023
With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and
LLY Down as Patients Regain Weight After Stopping Zepbound
03:02pm, Tuesday, 12'th Dec 2023
Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.
3 Best Profitable Stocks to Invest in Using Net Income Ratio
07:31am, Tuesday, 12'th Dec 2023
Perdoceo Education (PRDO), Novo Nordisk (NVO) and Merchants Bancorp (MBIN) have been selected as the top picks with a high net income ratio.
Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
02:42am, Tuesday, 12'th Dec 2023
Novo Nordisk reported strong Q3 results, beating analyst consensus on both top line and earnings. The SELECT CVOT study showed that Wegovy/Ozempic treatment may reduce the risk of death from cardiovas
Novo Nordisk: Everything investors need to know
04:47pm, Monday, 11'th Dec 2023
Yahoo Finance selected pharmaceutical firm Novo Nordisk (NVO) as it's 2023 Company of the Year. Developer of obesity medications Wegovy and Ozempic, Novo Nordisk stock has gained over 40% year-to-date
5 Reasons to be Bullish into 2024
04:32pm, Monday, 11'th Dec 2023
2023: Predicting is Futile, Interpreting is Priceless
Novo Nordisk: Yahoo Finance's Company of the Year, 2023
02:28pm, Monday, 11'th Dec 2023
Novo Nordisk (NVO) and more specifically its blockbuster weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street and well beyond this year, due to the company
Why Novo Nordisk's corporate structure stands out
01:34pm, Monday, 11'th Dec 2023
Yahoo Finance selected Novo Nordisk (NVO) as its Company of the Year for 2023, and there are plenty of reasons why. One interesting reason some investors may not know about, however, is its unique cor
6 Health Care Dividend Stocks To By Hand Over Fist
10:48am, Monday, 11'th Dec 2023
This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.
